Finance

Beta
Lists
N1VO34:BVMF
Նովո Նորդիսկ
28,83 R$
+0,21%
(+0,060) 1D
29 մյս, 13:41:20 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for N1VO34...
Open
29,02 R$
High
29,03 R$
Low
28,64 R$
Mkt. cap
155,47 մլրդ
Avg. vol.
26,20 հզր
Volume
8,74 հզր
52-wk high
57,25 R$
52-wk low
22,90 R$
Shares outstanding
3,39 մլրդ
No. of employees
68 հզր
Open
29,02 R$
High
29,03 R$
Low
28,64 R$
Mkt. cap
155,47 մլրդ
Avg. vol.
26,20 հզր
Volume
8,74 հզր
52-wk high
57,25 R$
52-wk low
22,90 R$
Shares outstanding
3,39 մլրդ
No. of employees
68 հզր
News stories
From sources across the web
Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations. The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
About Նովո Նորդիսկ
CEOMaziar Mike Doustdar
Employees67,9 հզր
Founded21 դեկ, 1923 թ.
HeadquartersBagsværd, Մայրաքաղաքային տարածաշրջան, Դանիա
Sector-
Websitenovonordisk.com
Last report
06 մյս, 2026 թ.
Fiscal period
Q1 2026
EPS / Est. (DKK)
6,63 DKK / 5,41 DKK
+22,48%beat
Revenue / Est. (DKK)
96,82 մլրդ / 71,56 մլրդ
+35,31%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in DKK
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in DKK
2025 թ. հնս
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
Revenue
76,86 մլրդ
74,98 մլրդ
79,14 մլրդ
96,82 մլրդ
Cost of goods sold
12,85 մլրդ
14,47 մլրդ
14,17 մլրդ
13,60 մլրդ
Cost of revenue
12,85 մլրդ
14,47 մլրդ
14,17 մլրդ
13,60 մլրդ
Research and development expenses
11,69 մլրդ
11,49 մլրդ
12,67 մլրդ
10,28 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
18,85 մլրդ
15,76 մլրդ
17,14 մլրդ
13,22 մլրդ
Operating expense
30,56 մլրդ
27,25 մլրդ
29,73 մլրդ
23,61 մլրդ
Total operating expenses
43,41 մլրդ
41,72 մլրդ
43,90 մլրդ
37,20 մլրդ
Operating income
33,45 մլրդ
33,25 մլրդ
35,24 մլրդ
59,62 մլրդ
Other non operating income
-
1,53 մլրդ
-241,00 մլն
-
EBT including unusual items
33,80 մլրդ
25,52 մլրդ
34,18 մլրդ
62,17 մլրդ
EBT excluding unusual items
33,80 մլրդ
35,09 մլրդ
37,62 մլրդ
62,17 մլրդ
Income tax expense
7,30 մլրդ
5,51 մլրդ
7,29 մլրդ
13,62 մլրդ
Effective tax rate
21,60%
21,60%
21,34%
21,90%
Other operating expenses
23,00 մլն
-
-81,00 մլն
106,00 մլն
Net income
26,50 մլրդ
20,01 մլրդ
26,89 մլրդ
48,56 մլրդ
Net profit margin
34,48%
26,68%
33,98%
50,15%
Earnings per share
5,96
4,50
6,04
6,63
Interest and investment income
5,31 մլրդ
307,00 մլն
4,41 մլրդ
-
Interest expense
-4,96 մլրդ
-
-4,97 մլրդ
-
Net interest expenses
356,00 մլն
307,00 մլն
-560,00 մլն
-
Depreciation and amortization charges
-
-
-
-
EBITDA
37,65 մլրդ
36,49 մլրդ
36,66 մլրդ
63,13 մլրդ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer